JPMorgan Chase & Co. Buys 326,095 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

JPMorgan Chase & Co. grew its position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 15.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 2,387,352 shares of the company’s stock after buying an additional 326,095 shares during the quarter. JPMorgan Chase & Co. owned about 0.06% of Kyverna Therapeutics worth $11,674,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of KYTX. FMR LLC bought a new stake in shares of Kyverna Therapeutics in the 3rd quarter worth approximately $33,000. Creative Planning purchased a new position in shares of Kyverna Therapeutics during the 3rd quarter worth approximately $54,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Kyverna Therapeutics in the 3rd quarter worth approximately $97,000. Federated Hermes Inc. purchased a new position in shares of Kyverna Therapeutics in the 2nd quarter valued at approximately $120,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Kyverna Therapeutics by 2,166.4% during the third quarter. BNP Paribas Financial Markets now owns 27,197 shares of the company’s stock valued at $133,000 after purchasing an additional 25,997 shares in the last quarter. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Trading Down 9.2 %

KYTX opened at $3.45 on Monday. The firm’s 50 day simple moving average is $4.51 and its two-hundred day simple moving average is $6.13. Kyverna Therapeutics, Inc. has a 1-year low of $3.41 and a 1-year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last released its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.01. The firm had revenue of $0.01 million during the quarter. As a group, sell-side analysts predict that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KYTX has been the subject of a number of recent research reports. UBS Group began coverage on shares of Kyverna Therapeutics in a research report on Thursday, October 10th. They set a “buy” rating and a $13.00 price target for the company. Rodman & Renshaw began coverage on shares of Kyverna Therapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $16.00 price objective for the company. Wells Fargo & Company cut their target price on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, November 15th. HC Wainwright decreased their price target on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, November 20th. Finally, RODMAN&RENSHAW raised Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $25.71.

Kyverna Therapeutics Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.